¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"clinical end point"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • clinical record
    ÀÓ»ó±â·Ï
  • clinical root
    ÀÓ»óÄ¡¾Æ»Ñ¸®, ÀÓ»óÄ¡±Ù
  • clinical sign
    ÀÓ»ó¡ÈÄ
  • clinical significance
    ÀÓ»óÀûÁ߿伺
  • clinical skill
    ÀÓ»ó¼ú±â
  • clinical trial
    ÀÓ»ó½ÃÇè
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • good clinical practice
    ÀǾàǰÀÓ»ó½ÃÇè°ü¸®±âÁØ
  • objective structured clinical examination
    °´°ü±¸Á¶È­Áø·á½ÃÇè
  • structured clinical interview
    ±¸Á¶È­ÀÓ»ó¸éÁ¢
  • acupuncture point
    °æÇ÷Á¡
  • blind point
    ¸ÍÁ¡
  • boiling point
    ²ú´ÂÁ¡, ºñµîÁ¡
  • conjugate point
    1. ÄÓ·¹Á¡ 2. °áÇÕÁ¡
  • corresponding point
    ´ëÀÀÁ¡
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • clinical medicine
    ÀÓ»óÀÇÇÐ
  • clinical mycology
    ÀÓ»óÁø±ÕÇÐ
  • clinical otosclerosis
    ¹ßÇö±Í°æÈ­Áõ
  • clinical record
    ÀÓ»ó±â·Ï
  • clinical root
    ÀÓ»óÄ¡¾Æ»Ñ¸®
  • clinical sign
    ÀÓ»ó¡ÈÄ
  • clinical significance
    ÀÓ»óÀûÁ߿伺
  • clinical skill
    ÀÓ»ó¼ú±â
  • clinical specimen
    ÀÓ»ó°Ë»ç¹°
  • clinical syndrome
    ÀÓ»óÁõÈıº
  • clinical trial
    ÀÓ»ó½ÃÇè
  • clinical ward
    ÀÓ»óº´µ¿
  • clinical dementia rating scale
    ÀÓ»óÄ¡¸ÅÆò°¡Ã´µµ
  • clinical target volume
    ÀÓ»óÇ¥ÀûüÀû
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • point estimation
    Á¡ÃßÁ¤¹ý(ËøÌ§ËøËÑ).
  • point mutation
    Á¡ µ¹¿¬º¯ÀÌ
  • point mutation
    Á¡µ¹¿¬º¯ÀÌ
  • point of basal convergence
    ±âÃÊÆøÁÖÁ¡(Ðñõ¨ÜßñÍïÇ).
  • point of condensation
    ÀÀÁýÁ¡(ëêó¢ïÇ).
  • point of convergence
    ÆøÁÖÁ¡(ÜßñÍïÇ).
  • point of fixation =p. of regard, fixa
    ÁÖ½ÃÁ¡(ñ¼ãÊïÇ).
  • point of maximal impulse
    ÃÖ´ë¹Úµ¿Á¡.
  • point of regard
    ÁÖ½ÃÁ¡.
  • point of symmetry
    ´ëĪÁ¡(ÓßöàïÇ).
  • point off axis
    ÃàÀÌÅ»ÁöÁ¡
  • point outside field
    Á¶»ç¿µ¿ª¹ÛÁöÁ¡
  • point prevalence
    ½ÃÁ¡À¯º´¼ö(ËàËøËôËÓ ).
  • point sampling
    Á¡ÃßÃâ¹ý(ËøÌ§Ì§ËÑ).
  • point under block
    ºí·ÏÇÏÁöÁ¡
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • clinical target volume, CTV
    ÀÓ»óÇ¥ÀûüÀû
  • clinical trial
    ÀÓ»ó½ÃÇè.
  • clinical trial
    ÀÓ»ó½ÃÇè
  • clinical unit
    ÀÓ»ó´ÜÀ§(¡­Ó¤êÈ).
  • clinical use
    ÀÓ»óÀû(ÀÎ) ÀÌ¿ë
  • clinical virology
    ÀÓ»ó¹ÙÀÌ·¯½ºÇÐ
  • clinical ward
    ÀÓ»óº´µ¿(¡­Ü»ÔÖ).
  • clinical-pathological correlation
    ÀÓ»ó-º´¸®ÇÐÀû »óÈ£°ü°è(ìúßÉ-Ü»×âùÊîÜ ßÓû»Î¼Ìõ)
  • controlled clinical study
    (Ãß°èÇÐÀû) °ü¸®È­(Ì§Ë­Ì°ËøË´ËöÌ´)(ÀÓ»ó)½ÃÇè( ËöË×ËàÌ´).
  • mycology, clinical
    ÀÓ»óÁø±ÕÇÐ
  • randomized clinical trial
    ¹«ÀÛÀ§ÀÓ»ó½ÇÇè
  • structured clinical interview
    ±¸Á¶È­µÈ ÀÓ»ó¸éÁ¢(ìúßÉØüïÈ).
  • validity of clinical study
  • acromial end
    ºÀ¿ì¸®³¡
  • advanced glycosylation end products
    ÁøÇ༺´çÈ­Á¾¸»»ý¼º¹°(òäú¼àõÓÐûùðûØÇßæà÷Úª)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • melting point
    À¶ÇØÁ¡(ë×ú°ïÆ)
  • point mutation
    Á¡º¯ÀÌ(ïÃܨì¶)
  • point quenching
    Á¡¼ÒÆÎ(ïÃá¼ÎÃ)
  • point symmetry
    Á¡´ëĪ(ïÃÓßöà)
  • restriction point
    Á¦ÇÑÁ¡(ð¤ùÚïÃ)
  • R point
    (å²) Restriction point
  • thermal death point
    ¿­»çÁ¡(æðÞÝïÃ)
  • thermal inactivation point
    ¿­ºÒȰ¼ºÈ­Á¡ (æðÝÕüÀàõûùïÃ)
  • three-point attachment
    ¼¼°÷ ºÎÂø(Üõó·)
  • three-point cross
    ¼¼Á¡ ±³Â÷(Îßó©)
  • three-point landing
    ¼¼°÷ ¾É±â
  • two-point cross
    ÀÌÁ¡±³Â÷(ì£ïÇÎßó©)
  • zero point
    ¿µÁ¡(ÖÃïÇ)
  • zero-point mutation
    ¿µÁ¡(ÖÃïÇ) º¯ÀÌ(ܨì¶)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CEEA curved end-to-end anastomosis [stapler]
EDCS end-diastolic chamber stiffness; end-diastolic circumferential stress
EDL end-diastolic length; end-diastolic load; estimated date of labor; extensor digitorum longus
EEA electroencephalic audiometry; end-to-end anastomosis
ES ejection sound; elastic stocking; electrical stimulus, electrical stimulation; electroshock; emergen...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
VLPP Valsalva Leak Point Pressure
AP acupuncture point
BPS branch point sequence
BP break point
FP fixation point
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • central bearing point
    Á᫐ ÁöÁöÁ¡
    Áß¾Ó ÁöÁö ÀåÄ¡ÀÇ Á¢ÃËÁ¡.
  • central point artifact
    Áß½ÉÁ¡ Àΰø¹°
  • conjugate point
    °ø¾× Á¡, ÄÓ·¹ Á¡, °áÇÕ Á¡
  • cutaneous trigger point
    ÇǺΠ¹ßÅëÁ¡
  • dew point
    ³ëÁ¡
  • distal point therapy
    ¿øµµ ÃëÇ÷ ¿ä¹ý
  • equivalence point
    ´ç·® Á¡
  • fixed point
    °íÁ¤Á¡
  • focal point
    ÃÊÁ¡
    ºûÀÌ Áý±¤ ·»Á ÅëÇØ Áö³ª°¥ ¶§ ±¤¼ÓÀÌ ÃÖ´ëÇÑ ³óÃàµÈ À§Ä¡.
  • freezing point depression
    ¾î´Â Á¡ °­ÇÏ
  • idiopathic trigger point mechanism
    Ư¹ß¼º ¹ßÅëÁ¡ ±âÀü
  • itchy point
    ¼Ò¾çÁ¡
  • jugal point
    Çù°¢ Á¡
    ÃøµÎ µ¹±â¿Í Çù°ñÀÇ ¾Õ ÂÊ ³¡ÀÇ À§ °¡ÀåÀÚ¸®°¡ À§·Î ³¯Ä«·Ó°Ô ±¸ºÎ·¯Áö´Â ÁöÁ¡.
  • jugomaxillary point
    Çù»ó¾ÇÁ¡
  • lacrimal point
    ´©Á¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
end-stage renal disease <nephrology> A patient with inadequate renal function to support life. Individuals with end-stage disease must rely in kidney dialysis or peritoneal dialysis to survive. End-stage renal disease may be caused by a number of problems including diabetes, sickle cell disease, hypertension and congenital renal disease (polycystic kidney disease).
(27 Sep 1997)
end-systolic volume The amount of blood in the ventricle at the end of the cardiac ejection period and immediately preceding the beginning of ventricular relaxation; a measurement of the adequacy of cardiac emptying, related to systolic function.
(05 Mar 2000)
end-tidal at the end of a normal expiration.
(05 Mar 2000)
end-tidal sample A sample of the last gas expired in a normal expiration, ideally consisting only of alveolar gas.
(05 Mar 2000)
zero end-expiratory pressure Airway pressure which, at the end of expiration, equals atmospheric pressure.
(05 Mar 2000)
Krause's end bulbs Nerve terminals in skin, mouth, conjunctiva, and other parts, consisting of a laminated capsule of connective tissue enclosing the terminal, branched, convoluted ending of an afferent nerve fibre; generally believed to be sensitive to cold.
Synonym: corpuscula bulboidea, bulboid corpuscles.
(05 Mar 2000)
flush end <molecular biology> The ends of a blunt-end DNA molecule, where both strands in the double-stranded DNA molecule are even with each other rather than one strand being longer than the other.
(09 Oct 1997)
Addison's clinical planes A series of plane's used as landmarks in thoracoabdominal topography; the trunk is divided vertically by a median plane from the upper border of the manubrium of the sternum to the pubic symphysis, by a lateral plane drawn vertically on either side through a point half way between the anterior superior iliac spine and the median plane at the interspinal plane, and by an interspinal plane passing vertically through the anterior superior iliac spine on either side; transversely the trunk is divided by a transthoracic plane passing across the thorax 3.2 cm above the lower border of the body of the sternum, by a transpyloric plane midway between the jugular notch of the sternum and the pubic symphysis, corresponding to the disc between the first and second lumbar vertebrae, and by an intertubercular plane passing through the iliac tubercles and cutting usually the fifth lumbar vertebra; the plane's formed on these lines, and also on transverse plane's cutting the upper edge of the manubrium and the upper edge of the pubic symphysis, constitute the clinical plane's of Addison.
(05 Mar 2000)
pathology, clinical A subspecialty of pathology which deals with the laboratory analysis of specimens of human blood and other fluids.
(12 Dec 1998)
chemistry, clinical The specialty of analytical chemistry applied to assays of physiologically important substances found in blood, urine, tissues, and other biological fluids for the purpose of aiding the physician in making a diagnosis or following therapy.
(12 Dec 1998)
pharmacology, clinical The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans.
(12 Dec 1998)
phase I clinical trial <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose.
They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies.
The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs.
(31 Dec 1997)
phase II clinical trial <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study.
(31 Dec 1997)
phase III clinical trial <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments.
Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials.
(31 Dec 1997)
Millon clinical multiaxial inventory A paper and pencil test, consisting of 20 clinical scales derived from 175 self-descriptive statements, and developed in 1977 for use in the assessment of psychopathology and the more enduring patterns of personality; specifically designed to correspond with some of the disorders of personality included in the Diagnostic and Statistical Manual of Mental Disorders used in diagnosis by mental health professionals.
Synonym: Millon clinical multiaxial inventory.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • rear end
    ÈĺÎ;ÈĹÌ;±ÃµÕÀÌ
  • rear-end
    ÈĺÎÀÇ;ÈĹÌÀÇ
  • receiving end
    ¹Þ´Â ÂÊ;½È¾îµµ ¹Þ¾ÆµéÀÏ ¼ö ¹Û¿¡ ¾ø´Â »ç¶÷;Èñ»ýÀÚ;Æ÷¼öÀÇ ¼öºñ À§Ä¡
  • repe's end
    ¹åÁ٠äÂï;±³¼ö¿ë ¹åÁÙ
  • tag end
    ¸¶Áö¸· ºÎºÐ(´ë¸ñ);³¡Å丷;ÀÚÅõ¸®;Á¾¸»;¸»±â
  • tail end
    ²¿¸®;³¡
  • tail-end Charlie
    ¸Ç µÚ¿¡ ¼± »ç¶÷
  • point
    Á¡,³¡,¿äÁ¡,Áö½ÃÇÏ´Ù,ÁöÀûÇÏ´Ù
  • point-of-sale
    ¸ÅÀåÀÇ
  • point-of-sales
    ¸ÅÀåÀÇ
  • Curie point (temperature)
    Äû¸®Á¡(¿Âµµ)(Àڱ⠺¯Å°¡ ÀϾ´Â ¿Âµµ)
  • Point Four
    Á¦4Á¤Ã¥(Truman ´ëÅë·ÉÀÇ ¹Ì°³¹ß Áö¿ª °æÁ¦ ¿øÁ¶ Á¤Ã¥)
  • ball point pen
    º¼Ææ
  • black point
    Èæ¼öº´
  • boiling point
    ºñµîÁ¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á